The National Institute for Health and Care Excellence has concluded that Roche’s Ocrevus should not be funded on the NHS for the treatment of primary progressive multiple sclerosis (PPMS) in adults.
News
Roche gearing up to file Tecentriq for breast cancer
Roche has unveiled data showing that a combination of Tecentriq and Abraxane significantly slashed the risk of disease worsening or death in some breast cancer patients.
CAR-T therapies leap towards EU approval
The stage has been set for approval of the first chimeric antigen T-cell therapies (CAR-T) in Europe, after Novartis’ Kymriah and Gilead’s Yescarta both won backing from the Committee for Medicinal Products for Human Use (CHMP).
NHS ‘Vanguards’ failing to reach potential, finds NAO
NHS England’s flagship vanguard programme has not delivered the depth and scale of transformed services originally aimed for, according to an investigation by the National Audit Office (NAO).
Celgene, Acceleron to file MDS therapy in the EU, US
Celgene and Acceleron Pharma are preparing to file their experimental myelodysplastic syndromes (MDS) therapy on both sides of the Atlantic on the back of promising data from a late-stage study.
Novartis to spin off eye unit Alcon
Novartis has announced plans to spin off its eye-care unit Alcon into a standalone entity.
Novo’s oral semaglutide bests MSD’s Januvia on HbA1c reduction
Novo Nordisk has presented data from a Phase IIIa study showing that an oral formulation of its GLP-1 analogue semaglutide was better at reducing blood sugar than MSD’s DPP-4 inhibitor Januvia in patients with type II diabetes.
EU approves Pfizer’s Xeljanz for psoriatic arthritis
The European Commission has approved Pfizer’s Xeljanz as a treatment for psoriatic arthritis (PsA), significantly expanding the drug’s scope.
FDA approves Pierre Fabre/Array Biotech melanoma combo
US regulators have issued a green light for Pierre Fabre and Array Biotech’s encorafenib/binimetinib combination therapy for advanced BRAF-mutant melanoma.
NHS England expands health and care record scheme
NHS England has announced two more regions chosen to become Local Health and Care Record Exemplars (LHCRE), tasked with establishing an integrated health and care record across a large population.
NICE backs Roche’s Alecensa
Roche’s Alecensa has won NICE backing as a treatment for a rare type of lung cancer, over-turning a prior decision to reject NHS funding for the drug.
EU approval for AcelRx’ Dzuveo
AcelRx’ Dzuveo has won approval in the European Unionl for the management of acute moderate to severe pain in medically monitored settings.
Priority review for Genentech’s flu drug
The US Food and Drug Administration will undertake a priority review of Genentech’s experimental flu drug baloxavir marboxil in people aged 12 years and older.
Summit shares plummet on DMD drug failure
Shares in Oxford University spin out Summit Therapeutics have taken a nosedive after the firm’s flagship drug ezutromid failed to hit targets in a mid-stage trial in patients with Duchenne muscular dystrophy (DMD).
Puma shares jump as breast cancer drug approval seems likely
Shares in Puma Biotechnology shot up nearly 30 percent on news that the firm’s breast cancer drug is now likely to get a green light from European regulators.
